With the Biological Development Center, the NMI Natural and Medical Sciences Institute in Reutlingen, together with the Werner Siemens Imaging Center (WSIC) at the Faculty of Medicine and the University Hospital of Tübingen, is laying the groundwork for the rapid and efficient commercialization of biotechnologically produced proteins – known as biologics – in the diagnostic and therapeutic markets. Biologics hold great potential, particularly for personalized medicine, to make treatments more specific and thus more successful. For the development pipeline in academia and industry – especially for SMEs and startups in the biotech sector – the Biologicals Development Center offers straightforward access to research opportunities. On-site, in close cooperation with academic groups and companies, interdisciplinary teams can conduct research on the design, production, functionalization, and testing of biologics, thereby accelerating their transfer into practical application.
Biologicals are also becoming increasingly important in the field of medical devices, for example, for coating implants, improving wound healing, or facilitating drug absorption. The NMI is already producing the first biologicals, which will be available starting in the middle of next year for conducting imaging experiments at the WSIC. Currently, the WSIC and the NMI are developing methods for labeling biologicals with short-lived tracers, such as the radioactive isotope fluorine-18, which has a half-life of just under two hours.
Such tracers, which can be produced on-site at the WSIC, offer, for the first time, the possibility of providing diagnostic monitoring for expensive immunotherapies. These therapies are, for example, increasingly being used in the fight against cancer. With these tracers, they can be tailored and adjusted to each individual patient.